Section (i): Brief account of Dexlansoprazole

Size: px
Start display at page:

Download "Section (i): Brief account of Dexlansoprazole"

Transcription

1 Section (i): Brief account of Dexlansoprazole Dexlansoprazole (DLP) is the R-enantiomer of lansoprazole (a racemic mixture of the R- and S-enantiomers). It is chemically (R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2- yl]methylsulfinyl)-1h-benzimidazole. Its empirical formula is: C 16 H 14 F 3 N 3 O 2 S, with a molecular weight of The structural formula is: DLP is a white to nearly white crystalline powder which melts with decomposition at 140 C. DLP is freely soluble in dimethylformamide, methanol, dichloromethane, ethanol, and ethyl acetate; and soluble in acetonitrile; slightly soluble in ether; and very slightly soluble in water; and practically insoluble in hexane. DLP is stable when exposed to light. DLP is more stable in neutral and alkaline conditions than acidic conditions [1]. DLP exhibits polymorphism. It is available as both crystalline and amorphous forms. Amorphous forms are generally more unstable than crystalline forms. DLP is marketed with a brand name DEXILANT (earlier known as KAPIDEX) [2]. DEXILANT is the first proton pump inhibitor (PPI) with a Dual Delayed Release (DDR) formulation designed to provide two separate releases of medication upon oral administration. The capsules contain DLP in a mixture of two types of enteric-coated granules with different ph-dependent dissolution profiles. DEXILANT is available in two dosage strengths: 30 mg and 60 mg, per capsule. DEXILANT is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals, Japan. DLP was approved by the U.S. Food and Drug Administration (FDA) on January 30, 2009 [3]. DLP DDR capsules approved for use of once-daily, oral treatment of heartburn 37

2 associated with symptomatic non-erosive gastro esophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. DEXILANT is based on a dual release technology, with the first quick release producing a plasma peak concentration about one hour after application, and the second retarded release producing another peak about four hours later [4]. DEXILANT works by turning off many of the millions of tiny pumps in stomach that produce acid. Clinical studies have shown that DEXILANT provides up to 24 hours of relief from heartburn due to acid reflux disease. Studies also showed DEXILANT heals damage (erosions) to the esophagus and keeps it from coming back. DLP drug substance and drug product is not official any pharmacopeia. Lansoprazole drug substance and drug product which is a recimic mixture of R and S enantiomers is official in USP. Literature survey revealed, LC-MS method have been reported for the quantitative determination of DLP in human plasma [5]. Few methods are reported for the quantification of lansoprazole and its impurities pharmaceutical preparations, biological fluids and in combination with other actives, these includes, colorimetry using dyes [6], UV spectrometry [7-9], HPLC [10-13] and chemo metric approach using HPLC [14] and TLC [15]. UPLC- MS/TOF[16] and HPLC[17] methods are reported for assay of lansoprazole oral suspension. A chiral LC method [18] reported for enantiomeric separation of DLP. Few papers are reported the synthesis, isolation, identification and characterization of the some of the impurities in lansoprazole [19-21]. So far no method is reported for determination of all 11 impurities of DLP. The reported assay methods of lansoprazole are not capable of quantifying DLP without interference from the other impurities. DLP is unstable when exposed to acid, base, peroxide and thermal degradations. Three unknown impurities (degradation products) present at a level below 0.05% in the initial samples of DLP capsules increased to a level of 0.5% in 3 M accelerated stability studies, i.e; 40 C/75%RH. The structures of these compounds are not reported in literature. This prompted the author to develop stability indicating HPLC methods for the assay and impurities. The three degradation impurities are enriched and isolated by using reversephase preparative liquid chromatography and characterized. 38

3 This chapter describes development and validation of a stability indicating methods for assay and impurities along with the identification, isolation and characterization of three unknown degradation products formed in DLP capsules during the stability studies. Though some of the impurities and degradation products were reported in the literature, identification, isolation and characterization of these degradation products is not reported to the best of our knowledge. Based LC-MS and NMR data the impurity I is characterized as 2-{(1-H- Benzoimidazol-2-ylsulfanyl)-[1-methyl-2-2,2,2-trifluoro-ethoxy)-4a,5,9b-triaza-indeno[2,1- a]inden-10-yl]-methyl}-3-methyl-pyridin-4-ol, with molecular formula C 30 H 23 F 3 N 6 O 2 S and molecular mass Impurity-II is characterized as 10-{(1-H-Benzoimidazol-2- ylsulfanyl)-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-yl]-methyl}-1-methyl-2-(2,2,2- trifluoro-ethoxy)- 4a,5,9b-triaza-indeno[2,1-a]indene with molecular formula C 32 H 24 F 6 N 6 O 2 S and molecular mass Impurity-III is characterized as 1-Methyl-2-(2,2,2-trifluoroethoxy)-4a,5,9b-triaza-indeno[2,1-a]indene with molecular formula C 16 H 12 F 3 N 3 O and molecular mass

4 Section (ii): Stability Indicating HPLC Assay method for Dexlansoprazole Capsules. This section reports the various aspects relating to the development and validation of stability indicating HPLC method for assay of Dexlansoprazole (DLP) capsules. 1. Experimental 1.1. Chemicals Samples of DLP API are received from process R&D, Dr Reddy s Laboratories, Hyderabad, India. DLP Capsules of 30 and 60 mg & all excipients are received from formulation R&D, Dr Reddy s Laboratories, Hyderabad, India. HPLC grade acetonitrile, methanol, triethylamine, sodium hydroxide and potassium dihydrogen phosphate are supplied by Merck, Darmstadt, Germany. High purity water is prepared by using Millipore Milli-Q plus purification system Determination of appropriate UV wavelength The suitable wavelength for the determination of DLP in diluent is identified by scanning over the range nm with a Shimadzu UV-160 (Shimadzu, Japan) double beam spectrophotometer Instrumentation and chromatographic conditions The M/s Waters HPLC System with a photo diode array detector is used for the method development and force degradation studies.the data is monitored and processed using Waters Empower Networking software. The HPLC system used for method validation is waters HPLC system with diode array detector and Agilent 1100 series LC system with variable wavelength detector (VWD). The data is monitored and processed by using waters Empower Networking Software. The chromatographic column used is an Xbridge C-18, 20mm x 4.6 mm column, with 5µ particle size with a Hypersil BDS C18, 10 mm x 4.6 mm guard column. The chromatographic condition follows a gradient program consisting of mixture of buffer and methanol in the ratio of 90:10 (v/v) as mobile phase A and of mixture of methanol and acetonitril in the ratio of 50:50 (v/v) as mobile phase B. The buffer is prepared as 0.05 M KH 2 PO 4 with 0.8% v/v triethylamine and finally ph is adjusted to 8.0. The gradient programme is : Time/%mobile phase A:% Mobile phase B is 0.0/75:25, 3.0/55:45, 4.0/55:45, 4.5/20:80, 5.5/20:80, 6.0/75:25, 8.0/75:25. The flow rate of the mobile phase is 1.2 ml min

5 The column temperature is maintained at 30ºC and the detection wavelength is 285 nm. The injection volume is 20µl Diluent: 0.1N NaOH and methanol in the ratio 75:25(v/v) is used as diluent Preparation of standard drug solution: The stock solution of DLP standard (equivalent to 0.68 mg ml -1 of DLP) is prepared in diluent. The working standard solution (0.068mg ml -1 of DLP for both 30 mg and 60 mg sample analysis purpose) is obtained by dilution of the stock solution in diluent. The Specimen chromatograms of diluent and standard is shown in fig Blank Standard Fig 2.2.1: Specimen chromatogram of diluent and DLP standard 0.068mg ml

6 1.6. Test Preparation for pharmaceutical formulations: Contents of ten capsules of DLP are emptied and weighed the enteric coated pellets in the capsules. Enteric coated pellets equivalent to 600 mg of DLP is weighed and transferred into a clean dry 1000mL volumetric flask for 60mg and 500 ml volumetric flask for 30mg. 0.1N NaOH is added upto 20% of total volume and, swirled to avoid aggregation and sonicated with frequent intermediate shaking to disperse the pellets. Then diluent is added to make 60% total volume and sonicated for 20 min with intermediate shaking. The temperature of the water in the sonicator bath is maintained between 20 ºC and 25ºC to avoid heating up the solution during soniation. Then volume is made up to total volume and mixed well. The concentration of this test stock solution is 0.6 mg of DLP per ml. The resulting solution is centrifuged at 4000 rpm for 10 min. 5 ml of the centrifugate is then diluted to 50 ml in a volumetric flask with diluent. The final concentration of this test preparation is 60 µg ml -1 of DLP. Placebo sample is prepared in the same way by taking the placebo equivalent its weight present in a test preparation.the Specimen chromatogram of placebo and test sample are shown in fig Placebo Test Fig 2.2.2: Overlay chromatogram of placebo and DLP Capsules. 42

7 1.7. Specificity: Regulatory guidances in ICH Q2A, Q2B, Q3B and FDA 21 CFR section 211, require the development and validation of stability-indicating potency of assays. However, the current guidance documents do not indicate detailed degradation conditions in stress testing. The forced degradation conditions, stress agent concentration and time of stress, are found to effect the % degradation. Preferably not more than 20% is recommended for active materials to make the right assessment of stability indicating nature of the chromatographic methods. The discovery of such stress conditions which can yield not more than 20% degradation is based on experimental studies. Chromatographic runs of placebo solution and samples subjected to force degradation are performed in order to provide an indication of the stability indicating properties and specificity of the method. The stress conditions employed are acid, base, neutral and oxidant media, moisture, heat and light. After the degradation treatments are completed, the samples are allowed to equilibrate to room temperature, neutralized with acid or base (as necessary), and diluted with diluent to get the working concentrations equivalent to test preparation. The samples are analyzed against a freshly prepared control sample (with no degradation treatment) and evaluated for peak purity by using photo diode array detector. Specific conditions are described below Placebo (excipients) interference: Placebo solutions are prepared by taking the weight of placebo approximately equivalent to its weight in the sample as described in the test preparation for DLP capsules dosage form Effect of acid hydrolysis : 300 mg of DLP pellets powder is treated with 100 ml of 1N HCl for 5 minutes on bench top with continuous shaking. The resulting solution is neutralized and then solution is prepared as per the test preparation to obtain a stock solution of 0.6 mg ml -1. Then the test stock is diluted with diluent to get the test preparation having final concentration of drug at about 60 µg ml

8 Effect of base hydrolysis 300 mg of DLP pellets powder is treated with 100 ml of 2N NaOH at 50 C using a heating water bath for 24 hours. The resulting stress solution is neutralized, equilibrated to room temparature and then solution is prepared as per the test preparation to obtain a stock solution of 0.6 mg ml -1. Then the test stock is diluted with diluent to get the test preparation having final concentration of drug at about 60 µg ml Effect of neutral hydrolysis 300 mg of DLP pellets powder is treated with 100 ml water at 50 C using a heating water bath for 24 hours. The resulting stress solution is equilibrated to room temperature and then treated same as per the test preparation to obtain a stock solution of 0.6 mg ml -1. Then the test stock is diluted with diluent to get the test preparation having final concentration of drug at about 60 µg ml Effect of oxidation 300 mg of DLP pellets powder is treated with 100 ml of 10%H 2 O 2 for 15 minutes on bench top with continuous shaking. The resulting solution is neutralized and then solution is prepared as per the test preparation to obtain a stock solution of 0.6 mg ml -1. Then the test stock is diluted with diluent to get the test preparation having final concentration of drug at about 60 µg ml Effect of moisture and heat To evaluate the effect of moisture and heat, DLP pellets powder is distributed as thin layer over two glass plates. One plate is then exposed to 25ºC/90% relative humidity for 9 days. Similarly DLP pellets powder in another plate is exposed in an oven at 105ºC for 1 hour. Then, both the samples are subjected to sample preparation using diluents as described in test preparation Effect of UV and visible light To study the photochemical stability of the drug product, the DLP pellets powder is exposed to 1200 K Lux hours of visible light and 200 Watt hours/ meter 2 of UV light by using photo stability chamber. After exposure the samples are subjected to sample preparation using diluents as described in test preparation. 44

9 1.8. Method validation Precision Precision (intra-day precision) of the assay method is evaluated by carrying out six independent assays of test sample of DLP capsules against qualified standard. The % RSD of six assays obtained is calculated. The intermediate precision (inter-day precision) of the method is also evaluated using two different HPLC systems and different HPLC columns in different days in the same laboratory Linearity Linearity study for assay method is made using six different concentration levels in the range of about µg ml -1 of DLP (corresponding to 6.6 to 250% of assay of nominal sample concentration of 60 µg ml -1.). The data of peak area versus concentration is subjected to least-square regression analysis Accuracy A study of recovery of DLP from spiked placebo is conducted. Samples are prepared by mixing placebo with DLP API equivalent to about 20%, 50%, 70%, 100%, 120%, and 150% of the assay of nominal sample concentration. Sample solutions are prepared in triplicate for each spike level as described in the test preparation. The % recovery is then calculated Robustness To determine the robustness of the developed method, experimental conditions are purposely altered one after the other to estimate their effect. Five replicate injections of standard solution are injected under each parameter change. The effect of flow rate, ph, column temperature and organic phase composition in mobile phase (methanol in mobile phase A and acetonitrile and methanol in mobile phase B) on the tailing factor of DLP peak and the %RSD for peak areas of replicate injections of standard is studied at flow rates of 1.0 ml min -1 and 1.4 ml min -1, at ph of 7.8 and 8.2, at column temperatures of 25ºC and 35ºC and organic phase compositions in mobile phase at + 10% respectively. 45

10 Solution stability and mobile phase stability The solution stability of DLP in the assay method is carried out by leaving solutions of both the test preparation and reference standard preparation in tightly capped volumetric flasks at room temperature for 48 hours. The same sample solutions is assayed after every 24 hours during the study period. The mobile phase stability is also carried out by assaying freshly prepared sample solutions against freshly prepared reference standard solutions at 24 hours interval for 48 hours. Mobile phase prepared is kept constant during the study period. The % RSD of assay of DLP is calculated for the study period during mobile phase stability and solution stability experiments. 2. Results and discussion 2.1. Determination of suitable wavelength The UV spectrum of DLP recorded in the range nm is illustrated in fig The spectrum indicates that 285 nm gives a good sensitivity for the assay. Fig 2.2.3: UV Spectra of DLP. 46

11 2.2. Optimization of chromatographic conditions The HPLC procedure is optimized with a view to develop a stability indicating assay method. Pure drug and stressed samples are injected and run in different solvent systems. Selection of mobile phase ph is done based on stability of DLP. Drug is found to be not stable and peak area continuously decreases in mobile phase with ph less than 7.0. Due to problem in stability of standard and test solutions, after several experiments the diluent is finalized as 0.1N NaoH and methanol in the ratio of 75 : 25 v/v. The ph of the diluents is about 11. Normal silica based column stationary phases not workable at ph 8.0. Most of the C18 column peak shape goes quickly as the silica starts dissolving at ph 8.0. Hence a choice is made to work with hybrid silica based columns. After screening of columns which can withstand for higher ph conditions, a choice of the column is made to waters Xbridge C18 column. A guard column is also chosen with C18 stationary phase in order to increase the life of Xbridge column. DLP is prone to degradation upon stability, it generates number of impurities during upon storage. As several late eluting non-polar degradants are possible to be present in the sample, isocratic methods are found to be not feasible due to high run times in order to elute all the degradants. As in the pharmaceutical industry, lot of potency analysis is needed to check the quality of the formulated products, a study is conducted to get the stability indicating method with shorter runtime. A number of experiments are done with different lengths of the columns and different mobile phase compositions and with different gradient programmes to separate all the degradants from DLP peak within short time. Eventually, satisfactory peak shape and satisfactory separation is achieved using a 20 mm x 4.6 mm, Xbridge C18 column with 5 µm with mobile phase A consisting of mixture of buffer and methanol in the ratio of 90:10 (v/v) as mobile phase A and of mixture of methanol and acetonitril in the ratio of 50:50 (v/v) as mobile phase B with a gradient programme of : Time/%mobile phase A:% Mobile phase B is 0.0/75:25, 3.0/55:45, 4.0/55:45, 4.5/20:80, 5.5/20:80, 6.0/75:25, 8.0/75:25. The optimum flow rate and column temperatures are found to be 1.2 ml min -1 and 30ºC respectively. 47

12 2.3. Method validation Precision Method repeatability (intra-day precision) is evaluated by assaying six samples, prepared as described in the test preparation. The mean % assay and % RSD for assay values are found to be and 0.2 respectively. These are well with in the acceptance criteria i.e. mean % assay between and RSD not more than 2.0 %. The intermediate precision (inter day precision) is performed by assaying six samples on different HPLC systems and different HPLC columns in different days as described in the sample preparation. The mean % assay and % RSD for assay values are found to be and 0.2 respectively. The result shows good precision of the method (table 2.2.1). Table 2.2.1: Results of precision of test method Sample No. Assay of DLP as % of labeled amount Intra-day precision Inter-day precision Mean RSD 0.2 % 0.2 % LOQ and LOD The LOQ and LOD are determined based on signal-to-noise ratios at analytical responses of 10 and 3 times the background noise, respectively. The LOQ is found to be 0.14 μg ml -1 with a resultant %R.S.D. of 0.6 (n = 5). The LOD is found to be μg ml Linearity A linear calibration plot for assay of DLP is obtained over the calibration range µg ml -1 and the correlation co-efficient is found to be greater than The result shown in fig indicates that an excellent correlation exists between the peak area and concentration of the analyte. 48

13 Fig.2.2.4: Linearity of detector response for DLP Accuracy The percentage recovery of DLP in pharmaceutical dosage form of capsules is shown in table ranged from 98.2 to and indicates high accuracy of the method. Table 2.2.2: Recovery results of DLP in DLP capsules Sample mg % level mg found No. added Recovery 1 20% % % % % % % % % % % % % % % % % % Mean % Recovery

14 Robustness In all the deliberately varied chromatographic conditions studied (flow rate, column temperature, ratio of acetonitrile and methanol composition in mobile phase), the tailing factor and the % RSD for the DLP peak area for five replicate injections of standard is found to be within the acceptable limit of not more than 2.0%, illustrating the robustness of the method (table 2.2.3). Table2.2.3: Results of Robustness study Observed value Parameter Variation Tailing factor %RSD 1.Flow rate 0.8 ml min ml min ml min Column temperature 25ºC ºC ºC Mobile phase A 90% (for methanol variation) 100% % Mobile phase B 90% (for acetonitrile variation) 100% % Mobile phase B 90% (for methanol variation) 100% % ph

15 Solution stability and mobile phase stability The difference in % assay of DLP test and standard preparations upon storage on bench top is found to be less than 1.2% up to 48 hours. Mobile phase stability experiments showed that tailing factor and % RSD are less than 1.2 and 0.3% respectively up to 48 hours. The solution stability and mobile phase stability experimental data confirms that standard and test preparations and mobile phase used during assay determination are stable up to 48 hours Results of specificity studies All the placebo and stressed samples prepared are injected into the HPLC system with photodiode array detector as per the described chromatographic conditions. Chromatograms of placebo solutions have shown no peaks at the retention time of DLP. This indicates that the excipients used in the formulation do not interfere in estimation of DLP in capsules formulation dosage form. Degradation is not found to be significant when exposed to light and humidity. In acid hydrolysis, base hydrolysis, water hydrolysis, thermal stress and oxidative studies, significant degradation is observed. All degradant peaks are well resolved from DLP peak in the chromatograms of all stressed samples. The chromatograms of the stressed samples are evaluated for peak purity of DLP using Waters Empower Networking software. For all forced degradation samples, the purity angle (the weighted average of all spectral contrast angles calculated by comparing all spectra in the integrated peak against the peak apex spectrum) is found to be less than threshold angle (the sum of the purity noise angle and solvent angle, the purity noise angles across the integrated peak) for DLP peak (table 2.2.4). This indicates that there is no interference from degradants in quantitating the DLP in capsules dosage form. Thus, this method is considered "Stability indicating. The chromatogram and purity plots of all stressed samples are shown in figs to

16 Table 2.2.4: Table of results of specificity Stress condition % Assay of stressed sample Purity Angle Purity Threshold Kept on bench top for 5 minutes with 1N HCl solution Stressed at 50 C in water bath for 24 hrs with 2N NaOH solution Kept on bench top for 15 minutes with 10% H 2 O 2 solution Stressed at 50 C in water bath for 24 hrs with water Exposed to visible light for 1.2million lux hours and UV light at 200 Watt hours/ meter Exposed to Dry heat at 105 C for about 1 hour. Exposed to humidity at 25 C, 90% RH for 9 days Fig 2.2.5: Chromatogram and purity plot of acid stressed DLP capsules. 52

17 Fig 2.2.6: Chromatogram and purity plot of base stressed DLP capsules. Fig 2.2.7: Chromatogram and purity plot of H 2 O 2 stressed DLP Capsules. 53

18 Fig 2.2.8: Chromatogram and purity plot of water stressed DLP capsules. Fig 2.2.9: Chromatogram and purity plot of light stressed DLP capsules. 54

19 Fig : Chromatogram and purity plot of Thermal stressed DLP capsules. Fig : Chromatogram and purity plot of humidity stressed DLP capsules. 55

20 3. Conclusion: A validated stability-indicating HPLC analytical method has been developed for the determination of DLP in delayed release capsules dosage form. The results of stress testing undertaken according to the International Conference on Harmonization (ICH) guidelines reveal that the method is selective and stability-indicating. The proposed method is simple, accurate, precise, specific and has the ability to separate the drug from degradation products and excipients of capsules dosage form. The method is suitable for the routine analysis of DLP in either bulk powder or in other pharmaceutical dosage forms. The HPLC procedure can be applied to the analysis of samples obtained during accelerated stability experiments to predict the expiry dates of DLP in bulk and in formulations. 56

21 Section (iii): Stability Indicating HPLC method for impurities Dexlansoprazole capsules. This section reports the various aspects relating to the development and validation of stability indicating HPLC method for impurities in DLP capsule dosage form. 1. Experimental 1.1. Chemicals Dexlansoprazole capsules (dual delayed release) are formulated in Dr Reddy s laboratories Ltd, Hyderabad, India. The standards of DLP and its impurities namely carboxylic acid, hydroxy benzimidazole, mercapto benzimidazole, N-oxide, nitrosulphoxide, sulphone, impurity I, sulphide, impurity II, impurity III and impurity M+467 are supplied by Dr. Reddy s laboratories limited, Hyderabad, India. The HPLC grade acetonitrile, ethanol and analytical grade KH 2 PO 4, NaOH and ortho phosphoric acid are purchased from Merck, Darmstadt, Germany. High purity water is prepared by using Milli Q Plus water purification system (Millipore, Milford, MA, USA). The chemical names and structures of DLP and its impurities are shown in the below. S.No Name of the Structure and IUPAC Name impurity 1 Dexlansoprazole 2 Carboxylic acid Impurity (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2- yl)methyl)sulfinyl)-1h-benzo[d]imidazole 3 Hydroxy- benzimidazole 1-(1H-benzo[d]imidazol-2-yl)-3-methyl-4-oxo-1,4- dihydropyridine-2-carboxylic acid 1H-benzo[d]imidazol-2-ol 57

22 4 Mercapto- benzimidazole 5 N-oxide 1H-benzo[d]imidazole-2-thiol 6 Nirosulphoxide (R)-2-(((1H-benzo[d]imidazol-2-yl)sulfinyl)methyl)-3-methyl-4- (2,2,2-trifluoroethoxy)pyridine 1-oxide 7 Sulphone 8 Cyclized dessulphur- des trifluoro ethyl sulphide adduct (Impurity I) 2-(((3-methyl-4-nitropyridin-2-yl)methyl)sulfinyl)-1Hbenzo[d]imidazole [[(1H-benzimidazole-2-yl)sulfinyl]methyl]-3-methyl-4-(2,2,2- trifluoroethoxy)-pyridine 1-oxide 2-(((1H-benzo[d]imidazol-2-yl)thio)(1-methyl-2-(2,2,2-58

23 trifluoroethoxy)benzo[4',5']imidazo[2',1':2,3]imidazo[1,5- a]pyridin-12-yl)methyl)-3-methylpyridin-4-ol. 9 Sulphide 10 Cyclized dessulphursulphide adduct (Impurity II) 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2- yl)methyl)thio)-1h-benzo[d]imidazole 12-(((1H-benzo[d]imidazol-2-yl)thio)(3-methyl-4-(2,2,2- trifluoroethoxy)pyridin-2-yl)methyl)-1-methyl-2-(2,2,2- trifluoroethoxy)benzo[4',5']imidazo[2',1':2,3]imidazo[1,5- a]pyridine 11 Cyclized dessulphur (Impurity III) 1-methyl-2-(2,2,2- trifluoroethoxy)benzo[4',5']imidazo[2',1':2,3]imidazo[1,5- a]pyridine. 59

24 12 Cyclized dessulphurmercapto benzimidazole adduct (Impurity M+467) 12-((1H-benzo[d]imidazol-2-yl)thio)-1-methyl-2-(2,2,2- trifluoroethoxy)benzo[4',5']imidazo[2',1':2,3]imidazo[1,5- a]pyridine 1.2. Determination of appropriate UV wavelength The suitable wavelength for the determination of DLP and its impurities is identified by taking the overlay spectra from nm of all impurities and DLP from PDA detector Instrumentation and chromatographic conditions The Waters HPLC System with a photo diode array detector is used for the method development and force degradation studies.the data is monitored and processed using Waters Empower Networking software. The HPLC system used for method validation is waters HPLC system with diode array detector and Agilent 1100 series LC system with variable wavelength detector (VWD). The chromatographic column used is an X-terra RP-18, 250mm x 4.6 mm column, with 3.5µ particle size with a 10 mm x 4.6 mm guard column. The chromatographic condition follows a gradient program consisting of mixture of buffer and acetonitrile in the ratio of 90:10 (v/v) as mobile phase A and of mixture of buffer and acetonitrile in the ratio of 30:70 (v/v) as mobile phase B. The buffer is prepared as 0.01 M KH 2 PO 4 (6.8g in 1000ml) in water with 1.0% v/v triethylamine and finally ph is adjusted to 7.0. The gradient program is Time/% Mobile phase B: 0.0/10, 50/60, 67/80, 85/80, 90/10, 100/10. The flow rate of mobile phase is 0.8 ml min -1. The column temperature is maintained at 25ºC and the detection wavelength is 285 nm. The injection volume is 10µl. Sample cooler temperature is used as 5 C. 60

25 1.4. Diluent: 0.1 N Sodium hydroxide and ethanol in the ratio of 3:5 (v/v) is used as a diluent Preparation of dexlansoprazole diluted standard solution: An accurately weighed amount of about 54 mg of DLP working standard is transferred into a 50 ml dried volumetric flask. 10 ml 0.1 N sodium hydroxide solution is added, sonicated to dissolve the material completely and diluted to volume with diluent and mixed well. This stock solution of DLP (equivalent to about 1.0 mg ml -1 of DLP) is then diluted to get a working DLP diluted standard solution (about 2 µg ml -1 of DLP) by dilution of the stock solution in with diluents along with 20% volume of 0.1N NaOH solution. The specimen chromatogram of diluent and DLP diluted standard solution is shown in fig Test Preparation for dexlansaprazole pharmaceutical formulations: Twenty capsules of DLP capsules (dual delayed release) are weighed and the contents are emptied and the pellets are transferred into a clean dry poly bag. Pellets equivalent to about 300 mg of DLP are transferred into a 500 ml volumetric flask. 100 ml of 0.1 N sodium hydroxide solution is first added and sonicated for about 10 minutes to disperse the pellets. Then 250 ml of diluent is added and, sonicated for 15 minutes with intermediate shaking. The temperature of water in sonicator bath is maintained between 20 C to 25 C. The volume is then made up with diluent and mixed well. A portion of the above solution is centrifuged in a centrifuge tube with cap at RPM for 5 minutes. The resultant clear supernatant solution is used for injection. Always freshly prepared solutions are used. Placebo sample is prepared in the same way by taking the placebo equivalent its weight present in a test preparation. The specimen chromatogram of placebo and test samples is shown in fig and

26 Diluent Diluted standard Fig 2.3.1: Specimen chromatograms of diluent and DLP diluted standard. Placebo Fig 2.3.2: Specimen chromatogram of placebo for DLP capsules. 62

27 Fig 2.3.3: Specimen chromatogram of DLP capsules test sample spiked with known impurities. 63

28 1.7. Specificity: Regulatory guidances ICH Q2A, Q2B, Q3B and FDA 21 CFR section 211, require the development and validation of stability-indicating impurities method for all pharmaceutical dosage forms. However, the current guidance documents do not indicate detailed degradation conditions in stress testing. The forced degradation conditions, stress agent concentration and time of stress, are found to effect the % degradation. Not more than 20% degradation is recommended for active materials to make the right assessment of stability indicating nature of the chromatographic methods. The optmisation of such stress conditions which can yield not more than 20% degradation is based on experimental study. Chromatographic runs of placebo and samples subjected to force degradation are performed in order to provide an indication of the stability indicating properties and to establish the specificity of the method. The stress conditions employed are acid, base, neutral and oxidant media, moisture, heat and light. After the degradation treatments are completed, the samples are allowed to equilibrate to room temperature, neutralized with acid or base (as necessary), and diluted with diluent to get the working concentrations equivalent to test preparation. The stressed samples are subjected to assay analysis to assess the mass balance. The samples are analyzed against a freshly prepared control sample (with no degradation treatment) and evaluated for peak purity by using photo diode array detector. Specific conditions are described below Placebo (excipients) interference: Placebo solutions are prepared in triplicate by taking the weight of placebo approximately equivalent to its weight in the sample as described in the test preparation for DLP capsules dosage form Effect of acid hydrolysis About 300 mg of DLP pellets powder is treated with 25 ml of 1N HCl for 1 minute on bench top with continuous shaking. The resulting solution is immediately neutralized and then solution is prepared as per the test preparation to obtain a solution having final concentration of drug at about 0.6 mg ml Effect of base hydrolysis About 300 mg of DLP pellets powder is treated with 25 ml 1N NaOH at 60 C using a heating water bath for 24 hrs. The resulting stress solution is neutralized, equilibrated to room 64

29 temperature and then solution is prepared as per the test preparation to obtain a solution having final concentration of drug at about 0.6 mg ml Effect of neutral hydrolysis About 300 mg of DLP pellets powder is treated with 25 ml water at 60 C using a heating water bath for 9.5 hours. The resulting stress solution is neutralized, equilibrated to room temperature and then treated same as per the test preparation to obtain a solution having final concentration of drug at about 0.6 mg ml Effect of oxidation About 300 mg of DLP pellets powder is treated with 25 ml of 3%H 2 O 2 for 30 minutes on bench top with continuous shaking. The resulting solution is neutralized and then solution is prepared as per the test preparation to obtain a solution having final concentration of drug at about 0.6 mg ml Effect of moisture and heat To evaluate the effect of moisture and heat, DLP pellets powder is distributed as thin layer over two glass plates. One plate is exposed to 25ºC/90% relative humidity for 7 days. Similarly DLP pellets powder in another plate is exposed in an oven at 105ºC for 1 hour. Then, both the samples are subjected to preparation using diluents as described in test preparation Effect of UV and visible light To study the photochemical stability of the drug product, DLP pellets powder is exposed to 1200 K Lux hours of visible light and 200 Watt hours/ m 2 of UV light by using photo stability chamber. After exposure, the samples are subjected to preparation using diluents as described in test preparation. 65

30 1.8. Method validation Relative response factors of all Known impurities The relative retention times(rrts) and relative response factors (RRFs) of all known impurities are established against DLP. Different concentrations of DLP and its known impurities are injected into the chromatographic conditions developed. The linearity graphs are drawn for DLP and all its known impurities individually. The relative response factors are then calculated by dividing the slope of impurity by slope of DLP. The relative retention times(rrt s) and relative response factors (RRF s) of 11 known impurities are summarized in table Table 2.3.1: RRT and RRF of known impurities of DLP. S.No Name of the impurity RRT RRF 1 Carboxylic acid Impurity Hydroxy benzimidazole Mercapto benzimidazole N-oxide Nitrosulphoxide Sulphone Impurity I Sulphide Impurity II Impurity III Impurity M Precision Precision (intra-day precision) of the impurities method is evaluated by preparing six different solutions of test sample of DLP capsules spiked with known impurities and injected into the developed chromatographic conditions described above. % of impurities are calculated against a qualified DLP standard. RSD is then calculated for % of impurities individually obtained for six different preparations. The intermediate precision (inter day precision) of the method is also evaluated using different HPLC systems and different HPLC columns on different day in the same laboratory. 66

31 Limits of Detection (LOD) and Quantification (LOQ) The LOD and LOQ for DLP and its 11 known impurities are determined at a signalto-noise ratio of 3:1 and 10:1, respectively, by injecting a series of dilute solutions with known concentrations. Precision study is also carried out at the LOQ level by injecting six individual preparations and % RSD is calculated Linearity Linearity test solutions for DLP and all its known impurities are prepared by diluting stock solutions to the required concentrations. The solutions are prepared at different concentration levels from LOQ to equal to or more than 150% of the specification concentration level for DLP and its all known impurities. The solutions are then injected into the chromatographic conditions developed. The data of peak area versus concentration is subjected to least-square regression analysis Accuracy A study of recovery of DLP and its 11 known impurities from placebo is conducted. Samples are prepared by mixing placebo with DLP as per the formulation composition and then spiking all the known impurities at different spike levels starting from LOQ to 150% of the specification level. Sample solutions are prepared in triplicate for each spike level as described in the test preparation and injected into the chromatographic conditions developed. The % recovery is then calculated against DLP diluted standard and by using relative response factor and compared against the known amounts of impurities spiked Robustness To determine the robustness of the developed method, experimental conditions are deliberately altered and the elution patterns, tailing factor and resolution between its impurities are evaluated. The effect of flow rate is studied at 0.6 ml ml -1 and 1.0 ml min -1. The effect of the column temperature is studied at 20ºC and 30ºC instead of 25ºC. The effect of ph is studied using mobile phase containing buffer with ph 7.0 ± 0.2. The effect of the percent organic strength is studied by varying acetonitrile by 10 to +10% while other mobile phase components were held constant. 67

32 Solution stability and mobile phase stability The stability of DLP and its impurities in solution for the impurities method is determined by leaving spiked sample solution in a tightly capped volumetric flask at room temperature on bench top and refrigerator and by measuring the amounts of the impurities at different intervals. The stability of mobile phase is also determined by analysing freshly prepared solution of DLP and its impurities for 3 days by using the same mobile phase during the study period. 2. Results and discussion 2.1. Determination of suitable wavelength The UV spectrum of DLP and its 11 known impurities are extracted in PDA detector from nm and is illustrated in fig The spectrum indicates that 285 nm gives a good sensitivity for the all impurities of DLP. Fig 2.3.4: UV Spectra of DLP and its impurities Optimization of chromatographic conditions The HPLC procedure is optimized with a view to develop a stability indicating impurities method. Pure drug and stressed samples are injected and run in different solvent systems. Selection of mobile phase ph is done based on stability of DLP. Drug is found to be not stable and impurities peak area continuously decreases in mobile phases with ph less than 7.0. Due to the problem in stability of standard, test and impurity solutions, after several experiments the diluent is finalized as 0.1N NaOH and ethanol 75: 25 v/v. The ph of the diluent is about 11. Normal silica based column stationary phases not workable beyond ph 8.0. Most of the C18 column peak shape goes quickly as the silica starts dissolving beyond 68

33 ph 8.0. Hence a choice is made to work with hybrid silica based columns. After screening of columns which can withstand for higher ph conditions, a choice of the column is made to waters X-terra RP18 column. A guard column is also chosen with C18 stationary phase in order to increase the life of analytical column. DLP is prone to degradation upon stability, it generates number of impurities upon storage. As several late eluting non-polar degradants are found in the sample, isocratic method is found to be not feasible in order to elute all the degradants. As in the pharmaceutical industry, lot of stability analysis is needed to check the quality of the formulated products for shelf life determination, a study is conducted to get the stability indicating method which can separate all known unknown impurities satisfactorily. A number of experiments are done with different columns and different mobile phase compositions and with different gradient programmes to separate all the degradants from each other and from DLP peak. Eventually, satisfactory peak shape and satisfactory separation is achieved using a 250 mm x 4.6 mm, X-terra RP18 column with 3.5 µm with mobile phase consisting of mixture of buffer (ph 7.0) and acetonitrile in the ratio of 90:10 (v/v) as mobile phase A and of mixture of buffer (ph 7.0) and acetonitrile in the ratio of 30:70 (v/v) as mobile phase B with a gradient programme of Time/% Mobile phase B : 0.0/10, 50/60, 67/80, 85/80, 90/10, 100/10. The optimum flow rate and column temperatures are found to be 0.8 ml min -1 and 25ºC. As there are 11 known impurities which are differing in polarity very significantly, with carboxylic acid impurity being most polar and impurity M+467 being most non polar, it is learnt during the experiments that a run time of 100 min is necessary. Especially, the separation between impurity I & sulphone and the separation between impurity II and III is found to be critical. The column length reduction or making the faster gradient is not successful in reducing the run time. Different ph conditions are also experimented without success. Different buffers in mobile phase also explored but KH 2 PO 4 with triethylamine as ion pair is found to be showing the best separations especially between unknown and known impurities when samples of stress solutions are evaluated. The wavelength of 285 nm is found to be best suitable for all known and unknown impurities estimation, as all the impurities are having good response at this wavelength. A test concentration of 0.6 mg ml -1 with an injection volume of 10µl is found to provide adequate sensitivity to the method wherein the LOQ of DLP and its known impurities is less than the reporting threshold as per ICH. Due to limited stability of solution of test sample, selection of sample cooler temperature as 5 C is found necessary. 69

34 2.3. Method validation Precision The precision of test method (intra-day precision) is evaluated by analyzing six test samples of DLP capsules by spiking test preparation with DLP impurities blend solution to get about 0.2 to 0.3% of carboxylic acid, hydroxy benzimidazole, mercapto benzimidazole, N- Oxide, nitrosulphoxide, impurity I, sulphide, impurity II, impurity III and impurity M+467 and about 0.4% of sulphone. Six different test preparations having placebo equivalent to test and spiked with about 0.25% of DLP are prepared and injected into the chromatographic condition developed. Relative standard deviations of % of DLP and its 11 known impurities were evaluated. Inter-day Precision study is conducted on a different day with different mobile phase, with different HPLC and different column. Six different test preparations of sample are prepared similar to intra-day precision and the relative standard deviations of % of DLP and its 11 known impurities are evaluated. The % RSD values are presented in table and % RSD values of less than 15% for DLP and its 11 known impurities shows that method is precise and work satisfactorily on different day, with different column and HPLC LOQ and LOD The limit of detection, limit of quantification are determined by following signal to noise ratio method. A precision study also conducted at LOQ level for DLP and its 11 known impurities. The results shows that method is sensitive enough to quantify impurities well below the ICH reporting threshold of 0.1%, as LOQ values are in the range of 0.02% to 0.05%. The data is summarized in table

35 Linearity A linear calibration plot for DLP and its 11 known impurities is drawn over the calibration range LOQ to 150% of the specification levels. Correlation co-efficient for DLP and its 11 known impurities is found to be greater than The regression analysis results are shown in table The results indicates that an excellent correlation exists between the peak area and concentration of the analyte for DLP and its 11 known impurities. The linearity graphs are presented as figure to Accuracy The percentage recovery of DLP and its 11 known impurities in presence of placebo matrix of DLP capsules from LOQ to 150% spike level are in the range of 90.9% to 109.2%. The LC chromatogram of test preparation spiked with all 11 known impurities is shown in Fig The % recovery values for DLP and impurities are presented in table The data shows that the method is having capability to estimate accurately all 11 known impurities of DLP in DLP capsules. 71

36 Table 2.3.2: Results of Inter day precision of test method for DLP and its 11 known impurities. Sample No. DLP Carboxylic acid Impurity Hydroxy benzimi dazole Mercapto benzimid azole N- Oxide Nitro sulph oxide Sulph one Impurity I Sulphide Impurity II Impurity III Impurity M Avg %RSD Table 2.3.3: Results of Intra-day precision of test method for DLP and its 11 known impurities. Sample No. DLP Carboxylic acid Impurity Hydroxy benzimi dazole Mercapto benzimid azole N- Oxide Nitro sulph oxide Sulph one Impurity I Sulphide Impurity II Impurity III Impurity M Avg %RSD

37 Table 2.3.4: LOD, LOQ data of DLP and its impurities Parameter DLP Carboxylic acid Impurity Hydroxy benzimida zole Mercapto benzimid azole N-Oxide Nitrosul phoxide Sulphone Impurity I Sulphide Impurity II Impurity III Impurity M+467 LOD In % S/N ratio LOQ In% S/N ratio Precision at LOQ (%RSD*) * RSD for 6 determinations. 73

38 Figure : Linearity graphs of DLP and its impurities. 74

39 Figure : Linearity graphs of DLP impurities. 75

40 Fig.2.3.7: Linearity graphs of DLP impurities. 76

41 Table 2.3.5: Recovery results of DLP impurities in pharmaceutical dosage forms Spike level DLP Carboxylic acid Impurity Hydroxy benzimida zole Mercapto benzimid azole N-Oxide Nitrosul phoxide Sulphone Impurity I Sulphide Impurity II Impurity III Impurity (M+467) LOQ 101.4(2.0) 102.2(5.4) 103.9(6.6) 103.4(0.0) 97.5(1.6) 90.9(5.4) 107.6(0.7) 96.4(4.6) 94.6(3.9) 96.7(3.2) 96.6(3.5) 99.9(1.9) 50% 101.1(1.2) 102.7(4.3) 102.9(0.6) 91.4(0.0) 100(1.2) 91.3(0.6) 97.7(1.6) 103.8(0.6) 102.0(1.1) 102.6(3.3) 107.3(1.4) 102.7(1.0) 75% 99.6(0.7) 101.5(3.8) 105.3(0.7) 91.1(0.9) 97.6(0.7) 92.3(1.3) 98.1(0.5) 102.6(0.8) 96.5(0.7) 100.7(3.7) 105.6(2.4) 101.1(0.7) 100% 99.0(0.7) 98.1(2.0) 104.5(0.5) 91.1(0.8) 97.1(0.4) 94.0(1.0) 97.3(0.5) 105.4(1.2) 97.1(0.7) 102.2(2.1) 109.2(2.4) 101.2(0.1) 125% 94.5(0.5) 99.6(3.1) 104.2(0.6) 93.7(0.8) 98.1(0.5) 95.0(0.6) 98.3(0.7) 101.0(1.1) 99.2(0.8) 101.9(1.5) 106.5(4.1) 101.3(0.6) 150% 94.1(1.4) 100.0(1.6) 99.0(0.6) 92.0(0.6) 96.6(0.7) 93.6(0.7) 96.6(0.6) 97.8(2.3) 96.5(0.9) 108.0(0.7) 108.5(0.5) 102.5(0.7) Values given in parenthesis represent standard deviation of triplicate results. 77

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC. 7. Stability indicating analytical method development and validation of and in capsule dosage form by HPLC. 7.1 INSTRUMENTS AND MATERIALS USED 7.1.1 INSTRUMENTS 1. Shimadzu LC-2010 CHT with liquid chromatograph

More information

A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation

A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation Pharmaceutical Research A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation Manisha Puranik* a, Sailesh Wadher b and Kritika

More information

Impact factor: 3.958/ICV: 4.10 ISSN:

Impact factor: 3.958/ICV: 4.10 ISSN: Impact factor: 3.958/ICV: 4.10 ISSN: 0976-7908 99 Pharma Science Monitor 9(4), Oct-Dec 2018 PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES Journal home page: http://www.pharmasm.com

More information

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW 75 CHAPTER 3 DEVELOPMENT AND APPLICATION OF STABILITY-INDICATING HPLC METHOD FOR THE DETERMINATION OF NEVIRAPINE AND ITS IMPURITIES IN COMBINATION DRUG PRODUCT 3.1 INTRODUCTION OF DOSAGE FORM AND LITERATURE

More information

CHAPTER - IV. Acharya Nagarjuna University, Guntur 105

CHAPTER - IV. Acharya Nagarjuna University, Guntur 105 CHAPTER - IV Acharya Nagarjuna University, Guntur 105 A STABILITY-INDICATING LC METHOD FOR LENALIDOMIDE Lenalidomide, 3-(4-amino-1-oxo-3H-isoindol-2-yl) piperidine-2, 6-dione (fig. 4.1), is a novel oral

More information

Validation of Stability-Indicating RP-HPLC Method for the Assay of Ibrutinib in Pharmaceutical Dosage form

Validation of Stability-Indicating RP-HPLC Method for the Assay of Ibrutinib in Pharmaceutical Dosage form Validation of Stability-Indicating RP-HPLC Method for the Assay of Ibrutinib in Pharmaceutical Dosage form 8.1 Introduction Ibrutinib (IBR) is an anticancer drug targeting B-cell malignancies (blood cancer

More information

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY CHAPTER 9 DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY CHAPTER 9 Determination of drug release during

More information

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS Issn No: 976-39 RESEARCH ARTICLE STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS CHETLAPALLI SATYA SRINIVAS 1, P.RENUKA DEVI 2 and GAMPA VIJAYAKUMAR*

More information

Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Anagrelide HCl in Pharmaceutical Formulation

Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Anagrelide HCl in Pharmaceutical Formulation ISSN 0976 3333 Available Online at www.ijpba.info International Journal of Pharmaceutical & Biological Archives 2013; 4(2): 342-346 ORIGINAL RESEARCH ARTICLE Development and Validation of Stability Indicating

More information

Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form

Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page: ISSN: 2320-2831 Research article Open Access Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form

More information

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD TO DETERMINE CINITAPRIDE HYDROGEN TARTARATE IN BULK AND PHARMACEUTICAL FORMULATION

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD TO DETERMINE CINITAPRIDE HYDROGEN TARTARATE IN BULK AND PHARMACEUTICAL FORMULATION Research Article ISSN:2230-7346 Journal of Global Trends in Pharmaceutical Sciences Vol.3, Issue 2, pp -619-627, April June 2012 DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD TO DETERMINE CINITAPRIDE HYDROGEN

More information

Volume 6, Issue 2, January February 2011; Article-015

Volume 6, Issue 2, January February 2011; Article-015 Research Article DEVELOPMENT AND VALIDATION OF A RP-HPLC METHOD FOR THE DETERMINATION OF DAPOXETINE HYDROCHLORIDE IN PHARMACEUTICAL FORMULATION USING AN EXPERIMENTAL DESIGN Pratik Mehta*, Ujjwal Sahoo,

More information

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68 Research Article Stability indicating RP-HPLC Method for Determination of FexoFenadine Hydrochloride and its Related Substances in Active Pharmaceutical Substance Abhay Gupta* 1, Dr. Birendra Srivastava,

More information

STABILITY INDICATING RP HPLC METHOD FOR ANALYSIS OF DORZOLAMIDE HCl IN THE BULK DRUG AND IT S PHARMACEUTICAL DOSAGE FORM

STABILITY INDICATING RP HPLC METHOD FOR ANALYSIS OF DORZOLAMIDE HCl IN THE BULK DRUG AND IT S PHARMACEUTICAL DOSAGE FORM International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 3, Issue 3, 2011 Research Article STABILITY INDICATING RP HPLC METHOD FOR ANALYSIS OF DORZOLAMIDE HCl IN THE BULK DRUG

More information

Development And Validation Of Rp-Hplc Method For Determination Of Velpatasvir In Bulk

Development And Validation Of Rp-Hplc Method For Determination Of Velpatasvir In Bulk International Journal of Engineering Science Invention (IJESI) ISSN (Online): 2319 6734, ISSN (Print): 2319 6726 www.ijesi.org PP. 36-41 Development And Validation Of Rp-Hplc Method For Determination Of

More information

Method Development and Validation for the Estimation of Darunavir in Rat Plasma by RP-HPLC

Method Development and Validation for the Estimation of Darunavir in Rat Plasma by RP-HPLC World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original

More information

Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form

Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form Indian Journal of Chemical Technology Vol. 13, May 2006, pp. 242-246 Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form Vinay Saxena a *, Zahid Zaheer b & Mazhar

More information

RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet formulation

RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet formulation 221 IJPAR Volume 2 Issue 4 Oct - Dec -2013 ISSN: 2320-2831 Available Online at: [Research article] RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet formulation Jeyabaskaran.M

More information

Pelagia Research Library

Pelagia Research Library Available online at www.pelagiaresearchlibrary.com Der Chemica Sinica, 2011, 2 (2): 230-239 ISSN: 0976-8505 CODEN (USA) CSHIA5 Stress degradation studies on Iloperidone and development of a stabilityindicating

More information

International Journal of Pharmacy and Pharmaceutical Sciences Vol 2, Issue 1, 2010

International Journal of Pharmacy and Pharmaceutical Sciences Vol 2, Issue 1, 2010 International Journal of Pharmacy and Pharmaceutical Sciences Vol 2, Issue 1, 2010 RP HPLC ESTIMATION OF EZETIMIBE IN TABLET DOSAGE FORMS NAGARAJU. P *, KRISHNACHAITHANYA. K, CHANDRABABU. D, SRINIVAS.

More information

A Stability Indicating UPLC Method for Candesartan in Bulk Drug Samples

A Stability Indicating UPLC Method for Candesartan in Bulk Drug Samples American Journal of Analytical Chemistry, 2012, 3, 704-709 http://dx.doi.org/10.4236/ajac.2012.310093 Published nline ctober 2012 (http://www.scirp.org/journal/ajac) A Stability Indicating UPLC Method

More information

Journal of Advanced Scientific Research DEVELOPMENT AND VALIDATION OF STABILITY-INDICATING RP-HPLC METHOD FOR ESTIMATION OF DABIGATRAN ETEXILATE

Journal of Advanced Scientific Research DEVELOPMENT AND VALIDATION OF STABILITY-INDICATING RP-HPLC METHOD FOR ESTIMATION OF DABIGATRAN ETEXILATE Damle et al, J Adv Sci Res, 2014, 5(3): 39-44 39 Journal of Advanced Scientific Research Available online through http://www.sciensage.info/jasr ISSN 0976-9595 Research Article DEVELOPMENT AND VALIDATION

More information

Method Development and Validation Of Prasugrel Tablets By RP- HPLC

Method Development and Validation Of Prasugrel Tablets By RP- HPLC Method Development and Validation Of Prasugrel Tablets By RP- HPLC K.Sonia*, Ndwabe Hamunyare, K.Manikandan Department of Pharmaceutical Analysis, SRM College of Pharmacy, SRM University, Kattankulathur,

More information

Development and Validation of Stability-Indicating RP-HPLC Method for Estimation of Atovaquone

Development and Validation of Stability-Indicating RP-HPLC Method for Estimation of Atovaquone Available online at www.ijpcr.com International Journal of Pharmaceutical and Clinical Research 2012; 4(4): 68-72 Research Article ISSN 0975 1556 Development and Validation of Stability-Indicating RP-HPLC

More information

Mashhour Ghanem 1 and Saleh Abu-Lafi 2 * ABSTRACT ARTICLE INFO

Mashhour Ghanem 1 and Saleh Abu-Lafi 2 * ABSTRACT ARTICLE INFO . Journal of Applied Pharmaceutical Science Vol. 3 (10), pp. 051-058, October, 2013 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2013.31009 ISSN 2231-3354 Validation of a Stability-Indicating

More information

Development and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in Multicomponents Syrups and Tablets

Development and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in Multicomponents Syrups and Tablets Development and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in s Syrups and Tablets Larisa Alagić-Džambić*, Midhat Vehabović, Edina Čekić, Mirsad Džambić Development Department,

More information

Chapter-4 EXPERIMENTAL WORK BY RP-HPLC

Chapter-4 EXPERIMENTAL WORK BY RP-HPLC Chapter-4 EXPERIMENTAL WORK BY RP-HPLC 4.0 EXPERIMENTAL WORK BY RP-HPLC 4.1. DEVELOPMENT AND VALIDATION OF AN RP-HPLC METHOD FOR THE DETERMINATION OF NIFLUMIC ACID 4.1.1. MATERIALS AND METHODS OF NIFLUMIC

More information

Scholars Research Library

Scholars Research Library Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2011, 3 (6):49-57 (http://scholarsresearchlibrary.com/archive.html) ISSN 0974-248X USA CODEN: DPLEB4

More information

Saudi Journal of Medical and Pharmaceutical Sciences

Saudi Journal of Medical and Pharmaceutical Sciences Saudi Journal of Medical and Pharmaceutical Sciences Scholars Middle East Publishers Dubai, United Arab Emirates Website: http://scholarsmepub.com/ ISSN 2413-4929 (Print) ISSN 2413-4910 (Online) Stability

More information

CYCLOSERINE Final text for addition to The International Pharmacopoeia. (November 2008) CYCLOSERINUM CYCLOSERINE

CYCLOSERINE Final text for addition to The International Pharmacopoeia. (November 2008) CYCLOSERINUM CYCLOSERINE December 2008 CYCLOSERINE Final text for addition to The International Pharmacopoeia (November 2008) This monograph was adopted at the Forty-third WHO Expert Committee on Specifications for Pharmaceutical

More information

Available online Research Article

Available online   Research Article Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2013, 5(12):1230-1236 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Rapid simultaneous determination of naproxen

More information

Appendix II- Bioanalytical Method Development and Validation

Appendix II- Bioanalytical Method Development and Validation A2. Bioanalytical method development 1. Optimization of chromatographic conditions Method development and optimization of chromatographic parameters is of utmost important for validating a method in biological

More information

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION Andrew J. Aubin and Tanya L. Jenkins Waters Corporation, Milford, MA, USA INTRODUCTION Benzocaine (4-Aminobenzoic

More information

Research Article. Identification and characterization of unknown impurity in zolmitriptan tablets by a sensitive HPLC method

Research Article. Identification and characterization of unknown impurity in zolmitriptan tablets by a sensitive HPLC method Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(12):548-553 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Identification and characterization of unknown

More information

Praveen kumar.m 1 *, Sreeramulu.J 2. *Corres.author: Mobile no: India.

Praveen kumar.m 1 *, Sreeramulu.J 2. *Corres.author: Mobile no: India. International Journal of ChemTech Research CODEN( USA): IJCRGG ISSN : 0974-4290 Vol.3, No.1, pp 321-328, Jan-Mar 2011 Development and validation of a Stabilityindicating Reversed-Phase High Performance

More information

METHOD DEVELOPMENT AND VALIDATION OF RALTEGRAVIR POTASSIUM AND RILPIVIRINE HCL BY HPLC AND HPTLC METHODS

METHOD DEVELOPMENT AND VALIDATION OF RALTEGRAVIR POTASSIUM AND RILPIVIRINE HCL BY HPLC AND HPTLC METHODS CHAPTER 6 METHOD DEVELOPMENT AND VALIDATION OF RALTEGRAVIR POTASSIUM AND RILPIVIRINE HCL BY HPLC AND HPTLC METHODS School of Pharmaceutical Sciences, Vels University 106 METHOD DEVELOPMENT AND VALIDATION

More information

2.1 2,3 Dichloro Benzoyl Cyanide (2,3 DCBC) and survey of. manufactured commonly for the bulk drug industry, few references were

2.1 2,3 Dichloro Benzoyl Cyanide (2,3 DCBC) and survey of. manufactured commonly for the bulk drug industry, few references were . Introduction.,3 Dichloro Benzoyl Cyanide (,3 DCBC) and survey of analytical methods,3-dcbc substance, is the although advanced intermediate,3-dcbc is a of lamotrigine well-known bulk drug chemical manufactured

More information

Department of Quality Assurance, Luqman College of Pharmacy, GULBARGA (K.S.) INDIA ABSTRACT

Department of Quality Assurance, Luqman College of Pharmacy, GULBARGA (K.S.) INDIA ABSTRACT Int. J. Chem. Sci.: 12(3), 2014, 871-879 ISSN 0972-768X www.sadgurupublications.com DEVELPMENT AND VALIDATIN F A RAPID RP HPLC METHD FR THE DETERMINATIN F CINITAPRIDE HYDRGEN TARTARATE IN PURE AND ITS

More information

Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form

Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form International Journal of PharmTech Research CDEN (USA): IJPRIF ISSN : 0974-4304 Vol.4, No.3, pp 1228-1232, July-Sept 2012 Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form Manzoor

More information

ARTEMETHER AND LUMEFANTRINE ORAL SUSPENSION:Final text for addition to The International Pharmacopoeia (November 2008)

ARTEMETHER AND LUMEFANTRINE ORAL SUSPENSION:Final text for addition to The International Pharmacopoeia (November 2008) November 2008 ` ARTEMETER AND LUMEFANTRINE RAL SUSPENSIN:Final text for addition to The International Pharmacopoeia (November 2008) Category. Antimalarial. Storage. Artemether and lumefantrine oral suspension

More information

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS CH.MOUNIKA*, M.KINNERA Research Article SIR.C.R.REDDY COLLEGE OF PHARMACEUTICAL SCIENCES, ELURU.

More information

Simultaneous Estimation of Residual Solvents (Isopropyl Alcohol and Dichloromethane) in Dosage Form by GC-HS-FID

Simultaneous Estimation of Residual Solvents (Isopropyl Alcohol and Dichloromethane) in Dosage Form by GC-HS-FID Asian Journal of Chemistry Vol. 21, No. 3 (2009), 1739-1746 Simultaneous Estimation of Residual Solvents (Isopropyl Alcohol and Dichloromethane) in Dosage Form by GC-HS-FID PRAVEEN KUMAR BALIYAN*, R.P.

More information

Development and Validation of a HPLC Method for Determination of Anastrozole in Tablet Dosage Form

Development and Validation of a HPLC Method for Determination of Anastrozole in Tablet Dosage Form ISSN: 0973-4945; CODEN ECJHAO E- Chemistry http://www.e-journals.net 2011, 8(2), 794-797. Development and Validation of a HPLC Method for Determination of Anastrozole in Tablet Dosage Form D.SATHIS KUMAR

More information

In the present analytical project, an attempt has been made to develop a simple, economical and reliable liquid

In the present analytical project, an attempt has been made to develop a simple, economical and reliable liquid ISSN: 0975-766X CODEN: IJPTFI Available Online through Research Article www.ijptonline.com STABILITY INDICATING HPLC METHOD FOR THE DETERMINATION OF GATIFLOXACIN IN PHARMACEUTICAL FORMULATIONS Syeda kulsum,

More information

KEYWORDS: Acetaminophen, Doxylamine succinate, Dextromethorphan hydrobromide.

KEYWORDS: Acetaminophen, Doxylamine succinate, Dextromethorphan hydrobromide. International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 3 Issue 7 July 2014 PP.08-12 Analytical method development and validation of acetaminophen,

More information

LUMEFANTRINUM LUMEFANTRINE

LUMEFANTRINUM LUMEFANTRINE July 2008 LUMEFANTRINE: Final text for addition to The International Pharmacopoeia (July 2008) This monograph was adopted at the Forty-second WHO Expert Committee on Specifications for Pharmaceutical Preparations

More information

Available online Research Article

Available online   Research Article Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2015, 7(10):483-494 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Validated RP-HPLC method for the simultaneous determination

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(2):274-279 A simple and validated reverse phase HPLC

More information

International Research Journal of Pharmaceutical and Applied Sciences Available online at Int. Res J Pharm. App Sci.

International Research Journal of Pharmaceutical and Applied Sciences Available online at  Int. Res J Pharm. App Sci. International Research Journal of Pharmaceutical and Applied Sciences Available online at www.irjpas.com Int. Res J Pharm. App Sci., 2012; 2(4):49-55 Research Article Method development and validation

More information

Quantitation of Sodium Bisulfite in Pharmaceutical Formulation by RP-HPLC

Quantitation of Sodium Bisulfite in Pharmaceutical Formulation by RP-HPLC Quantitation of Sodium Bisulfite in Pharmaceutical Formulation by RP-HPLC Chapter-3 Overview: The present chapter deals with the determination of sodium bisulfite (inorganic compound) as antioxidant in

More information

Journal of Chemical and Pharmaceutical Research, 2017, 9(1): Research Article

Journal of Chemical and Pharmaceutical Research, 2017, 9(1): Research Article Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2017, 9(1):118-122 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Development and Validation of High Performance Liquid

More information

ARTEMETHER AND LUMEFANTRINE TABLETS: Final text for addition to The International Pharmacopoeia (July 2008)

ARTEMETHER AND LUMEFANTRINE TABLETS: Final text for addition to The International Pharmacopoeia (July 2008) July 2008 ARTEMETER AND LUMEFANTRINE TABLETS: Final text for addition to The International Pharmacopoeia (July 2008) This monograph was adopted at the Forty-second W Expert Committee on Specifications

More information

Sarojamma. M et al, JGTPS, 2015, Vol. 6(2):

Sarojamma. M et al, JGTPS, 2015, Vol. 6(2): ISSN: 2230-7346 Sarojamma. M et al. / JGTPS / 6(2)-(2015) 2546 2551 (Research Article) Journal of Global Trends in Pharmaceutical Sciences Journal home page: www.jgtps.com RP-HPLC ASSAY METHOD DEVELOPMENT

More information

STABILITY INDICATING RP-HPLC METHOD FOR DETERMINATION OF EPROSARTAN IN PURE AND PHARMACEUTICAL FORMULATION

STABILITY INDICATING RP-HPLC METHOD FOR DETERMINATION OF EPROSARTAN IN PURE AND PHARMACEUTICAL FORMULATION STABILITY INDICATING RP-HPLC METHOD FOR DETERMINATION OF EPROSARTAN IN PURE AND PHARMACEUTICAL FORMULATION Praveen Kumar.M 1 *, Sreeramulu.J 2 1 Department of chemistry, Rayalaseema University, Kurnool-518002,

More information

ANALYTICAL METHOD PROCEDURES

ANALYTICAL METHOD PROCEDURES HPLC ASSAY AND RELATED SUBSTANCE Column Eurospher 100, C18, 25 x 0.40 cm 5µ Mobile Phase Buffer ph 2.0*: Acetonitrile (88:12 v/v) * Buffer ph 2 Potassium dihydrogen phosphate (KH 2 PO 4 ) - 0.68g Hepatane

More information

Reverse Phase High Performance Liquid Chromatography method for determination of Lercanidipine hydrochloride in bulk and tablet dosage form

Reverse Phase High Performance Liquid Chromatography method for determination of Lercanidipine hydrochloride in bulk and tablet dosage form Research Article ISSN: 0974-6943 M.V.Kumudhavalli et al. / Journal of Pharmacy Research 2014,8(11), Available online through http://jprsolutions.info Reverse Phase High Performance Liquid Chromatography

More information

Work plan & Methodology: HPLC Method Development

Work plan & Methodology: HPLC Method Development Work plan & Methodology: HPLC Method Development The HPLC analytical Method developed on the basis of it s chemical structure, Therapeutic category, Molecular weight formula, pka value of molecule, nature,

More information

LC Determination of Deferasirox in Pharmaceutical Formulation

LC Determination of Deferasirox in Pharmaceutical Formulation ISSN:2230-7346 Available online http://www.jgtps.com Research Article Journal of Global Trends in Pharmaceutical Sciences Vol.1, Issue 1, pp 42-52, October December 2010 LC Determination of Deferasirox

More information

INDICATING LIQUID CHROMATOGRAPHIC METHOD FOR QUANTIFICATION OF CIPROFLOXACIN HCL, ITS RELEATED SUBSTANCE AND TINIDAZOLE IN TABLET DOSAGE FORM

INDICATING LIQUID CHROMATOGRAPHIC METHOD FOR QUANTIFICATION OF CIPROFLOXACIN HCL, ITS RELEATED SUBSTANCE AND TINIDAZOLE IN TABLET DOSAGE FORM Innovare Academic Sciences International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 6, Issue 5, 2014 Original Article VALIDATED STABILITY INDICATING LIQUID CHROMATOGRAPHIC METHOD

More information

DEVELOPMENT AND VALIDATION OF ULTRA PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR ASSAY OF OMEPRAZOLE BLEND

DEVELOPMENT AND VALIDATION OF ULTRA PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR ASSAY OF OMEPRAZOLE BLEND Page38 Research Article Biological Sciences DEVELOPMENT AND VALIDATION OF ULTRA PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR ASSAY OF OMEPRAZOLE BLEND M.N Brinda 1*, Dr. V. Krishna Reddy 1, E.Sasikiran

More information

Research Article Available online at

Research Article Available online at Research Article Available online at www.jgtps.com ISSN: 2230-7346 Volume- 5, Issue -2, pp-1522-1527- April June (2014) DEVELOPMENT AND VALIDATION OF AN RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF CITICOLINE

More information

Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page:

Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page: Research Article CODEN: AJPAD7 ISSN: 2321-0923 Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page: www.ajpamc.com HPLC AND UV-SPECTROPHOTOMETRIC ESTIMATION OF TENELIGLIPTIN

More information

TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD

TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD APPENDIX V TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD Validating Chromatographic Methods. By David M. Bliesner Copyright 2006 John Wiley & Sons, Inc. 159 160 APPENDIX V Title: Effective: Document No:

More information

Analytical Method Development and Validation of Lafutidine in Tablet dosage form by RP-HPLC

Analytical Method Development and Validation of Lafutidine in Tablet dosage form by RP-HPLC International Journal of ChemTech Research CODEN( USA): IJCRGG ISSN : 0974-4290 Vol. 3, No.3, pp 1403-1407, July-Sept 2011 Analytical Method Development and Validation of Lafutidine in Tablet dosage form

More information

Research Article. Figure 1. Chemical structure of doxofylline. Indonesian J. Pharm. Vol. 24 No. 1 : ISSN-p :

Research Article. Figure 1. Chemical structure of doxofylline. Indonesian J. Pharm. Vol. 24 No. 1 : ISSN-p : Research Article Indonesian J. Pharm. Vol. 24 No. 1 : 14 21 ISSN-p : 0126-1037 DEVELOPMENT AND VALIDATION OF LIQUID CHROMATOGRAPHY AND SPECTROSCOPIC METHODS FOR THE ANALYSIS OF DOXOFYLLINE IN PHARMACEUTICAL

More information

Sravani and Haritha Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online)

Sravani and Haritha Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online) A new development and validated RP-HPLC method for the assay and related substances of Itraconazole in capsule dosage form Sarvani Paruchuri*, Haritha Pavani K Nimra College of Pharmacy, Vijayawada, Andhra

More information

International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: , ISSN(Online): Vol.9, No.7, pp , 2016

International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: , ISSN(Online): Vol.9, No.7, pp , 2016 International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 097-30, ISSN(Online): 255-9563 Vol.9, No.7, pp 399-06, 2016 Analytical Quality by Design Approach for Development of UV-Spectrophotometric

More information

SIMULTANEOUS RP HPLC DETERMINATION OF CAMYLOFIN DIHYDROCHLORIDE AND PARACETAMOL IN PHARMACEUTICAL PREPARATIONS.

SIMULTANEOUS RP HPLC DETERMINATION OF CAMYLOFIN DIHYDROCHLORIDE AND PARACETAMOL IN PHARMACEUTICAL PREPARATIONS. Ind. J. Anal. Chem Vol. 7 11. 2008 SIMULTANEOUS RP HPLC DETERMINATION OF CAMYLOFIN DIHYDROCHLORIDE AND PARACETAMOL IN PHARMACEUTICAL PREPARATIONS. Authors for correspondence : R. R. Singh1*, M. V. Rathnam,

More information

Dissolution Test 5 was validated using a Zodiac C18 brand of L1 column. The typical retention time for atorvastatin is about min.

Dissolution Test 5 was validated using a Zodiac C18 brand of L1 column. The typical retention time for atorvastatin is about min. Atorvastatin Calcium Tablets Type of Posting Posting Date 25 Jan 2019 Official Date 01 Feb 2019 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance In accordance with the Rules

More information

DEVELOPMENT AND VALIDATION OF NEW ANALYTICAL METHOD FOR BIOACTIVE COMPOUNDS

DEVELOPMENT AND VALIDATION OF NEW ANALYTICAL METHOD FOR BIOACTIVE COMPOUNDS OF Ph.D. THESISS ENTITLED DEVELOPMENT AND VALIDATION OF NEW ANALYTICAL METHOD FOR BIOACTIVE COMPOUNDS SUBMITTED TO KADI SARVA VISHWAVIDYALAYA, GANDHINAGAR, GUJARAT, INDIA FOR THE DEGREE OF DOCTOR OF PHILOSOPHY

More information

Development of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation)

Development of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation) Development of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation) TEENA OSWAL*, DR.SURYAKANT BHOSALE, DR. SONALI NAIK MET Institute Of Pharmacy Met Complex, Bandra Reclamation,

More information

International Journal of Pharma and Bio Sciences V1(1)2010 UV- SPECTROPHOTOMETRIC DETERMINATION OF TENATOPRAZOLE FROM ITS BULK AND TABLETS

International Journal of Pharma and Bio Sciences V1(1)2010 UV- SPECTROPHOTOMETRIC DETERMINATION OF TENATOPRAZOLE FROM ITS BULK AND TABLETS M. SUGUMARAN*, R.NAGESWARA RAO AND D. JOTHIESWARI Department of Pharmaceutical Analysis, Adhiparasakthi College of Pharmacy, Melmaruvathur- 603319,Tamilnadu,India. * Corresponding author murugesansugumaran@yahoo.com

More information

DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR ASSAY OF IRBESARTAN IN PURE AND PHARMACEUTICAL DOSAGE FORM

DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR ASSAY OF IRBESARTAN IN PURE AND PHARMACEUTICAL DOSAGE FORM Research Article DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR ASSAY OF IRBESARTAN IN PURE AND PHARMACEUTICAL DOSAGE FORM Praveen kumar.m 1 *, Sreeramulu.J 2 1 Department of Chemistry,

More information

Journal of Chemical and Pharmaceutical Research, 2017, 9(10): Research Article

Journal of Chemical and Pharmaceutical Research, 2017, 9(10): Research Article Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2017, 9(10):286-293 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Development and Validation of UPLC Method for the

More information

DEVELOPMENT AND VALIDATION OF NEW RP-HPLC METHOD FOR THE DETERMINATION OF AFLOQUALONE IN HUMAN PLASMA AND FORMULATION

DEVELOPMENT AND VALIDATION OF NEW RP-HPLC METHOD FOR THE DETERMINATION OF AFLOQUALONE IN HUMAN PLASMA AND FORMULATION INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article DEVELOPMENT AND VALIDATION OF NEW RP-HPLC METHOD FOR THE DETERMINATION OF AFLOQUALONE IN HUMAN

More information

Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC

Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC ISSN 2395-3411 Available online at www.ijpacr.com 248 Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC Mantha Vebkatesh* and A. Yasodha

More information

Journal of Drug Delivery and Therapeutics

Journal of Drug Delivery and Therapeutics Available online on 15.01.2018 at http://jddtonline.info Journal of Drug Delivery and Therapeutics Open Access to Pharmaceutical and Medical Research 2011-17, publisher and licensee JDDT, This is an Open

More information

Development and validation of stability indicating reverse phase high performance liquid chromatography method for Timolol Maleate

Development and validation of stability indicating reverse phase high performance liquid chromatography method for Timolol Maleate International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.6, No.5, pp 1429-1435, Sept-Oct 2014 Development and validation of stability indicating reverse phase high performance

More information

Dissolution study and method validation of alprazolam by high performance liquid chromatography method in pharmaceutical dosage form

Dissolution study and method validation of alprazolam by high performance liquid chromatography method in pharmaceutical dosage form Research Journal of Recent Sciences ISSN 2277-252 Dissolution study and method validation of alprazolam by high performance liquid chromatography method in pharmaceutical dosage form Abstract Rele Rajan

More information

Journal of Pharmaceutical and Biomedical Analysis Letters. Analysis Letters

Journal of Pharmaceutical and Biomedical Analysis Letters. Analysis Letters Naga Jyothi. C et al, JPBMAL, 2015, 3(1): 242 246 ISSN: 2347-4742 Journal of Pharmaceutical and Biomedical Analysis Letters Journal Home Page: www.pharmaresearchlibrary.com/jpbmal Research Article Open

More information

Chapter 5. Irbesartan. Page no. 64 to 80

Chapter 5. Irbesartan. Page no. 64 to 80 Page no. 64 to 80 , a nonpeptide tetrazole derivative, is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension and diabetic nephropathy [65]. It is a specific competitive

More information

Pelagia Research Library

Pelagia Research Library Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2014, 5(1):34-39 ISSN: 0976-8688 CODEN (USA): PSHIBD Advance simultaneous determination of paracetamol, thiocolchicoside and aceclofenac

More information

4.1 MATERIALS 4.2 EQUIPMENTS

4.1 MATERIALS 4.2 EQUIPMENTS 4.1 MATERIALS 1. Aceclofenac Moraceae Pharma Ltd., Uttarakhand, India 2. Diclofenac Arti Drugs Ltd., Mumbai, India 3. Paracetamol Moraceae Pharma Ltd., Uttarakhand, India 4. Para-aminophenol Hema Pharmaceuticals

More information

J Pharm Sci Bioscientific Res (4): ISSN NO

J Pharm Sci Bioscientific Res (4): ISSN NO Development and Validation of Stability Indicating Analytical Method for Simultaneous Estimation of Perindopril and Potassium in Their Combined Marketed Dosage Form ABSTRACT: Gurjeet Kaur*, Nikhil Patel

More information

Development And Validation Of Stability Indicating RP-HPLC Method For Estimation Of Ledipasvir And Sofosbuvir

Development And Validation Of Stability Indicating RP-HPLC Method For Estimation Of Ledipasvir And Sofosbuvir International Journal of Engineering Science Invention (IJESI) ISSN (Online): 2319 6734, ISSN (Print): 2319 6726 www.ijesi.org PP. 42-48 Development And Validation Of Stability Indicating RP-HPLC Method

More information

DEVELOPMENT AND VALIDATION OF A SPECTROPHOTOMETRIC METHOD FOR DETERMINATION OF DRONEDARONE IN BULK DRUG AND PHARMACEUTICAL FORMULATION

DEVELOPMENT AND VALIDATION OF A SPECTROPHOTOMETRIC METHOD FOR DETERMINATION OF DRONEDARONE IN BULK DRUG AND PHARMACEUTICAL FORMULATION Page186 Research Article Pharmaceutical Sciences DEVELOPMENT AND VALIDATION OF A SPECTROPHOTOMETRIC METHOD FOR DETERMINATION OF DRONEDARONE IN BULK DRUG AND PHARMACEUTICAL FORMULATION Kishore Konam 1 &

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2010, 2(5):399-417 Method develpopment and validation of Hydrochloride

More information

International Journal of Pharmaceutical Sciences and Drug Research 2016; 8(4):

International Journal of Pharmaceutical Sciences and Drug Research 2016; 8(4): Available online at www.ijpsdr.com International Journal of Pharmaceutical Sciences and Drug Research 2016; 8(4): 218-222 Research Article ISSN: 0975-248X CODEN (USA): IJPSPP Development and Validation

More information

Aripiprazole is a quinolinone derivative with the chemical name 7-[4- [4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)

Aripiprazole is a quinolinone derivative with the chemical name 7-[4- [4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H) 147 5.0 INTRODUCTION Aripiprazole is a quinolinone derivative with the chemical name 7-[4- [4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H) quinolinone. Aripiprazole is a psychotropic agent

More information

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF IVABRADINE HCL IN BULK AND FORMULATION

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF IVABRADINE HCL IN BULK AND FORMULATION ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF IVABRADINE HCL IN BULK AND FORMULATION Gauri Korgaonkar *, Vaishali B. Jadhav, Ashish Jain Shri d.d. vispute college of pharmacy & research center, Panvel,

More information

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF CEFIXIME

More information

Isocraticc Reverse Phase HPLC Method-Determination and Validation of Cilostazol

Isocraticc Reverse Phase HPLC Method-Determination and Validation of Cilostazol K. Krishna Chaitanya et al IJCPS, 2013: Vol. 1(4):257-262 ISSN: 2321-3132 Research Article International Journal of Chemistry and Pharmaceutical Sciences IJCPS, 2013: Vol. 1(4): 257-262 (Online at www.pharmaresearchlibrary.com/ijcps)

More information

A VALIDATED RP HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF OMEPRAZOLE AND CINITAPRIDE IN COMBINED DOSAGE FORMS

A VALIDATED RP HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF OMEPRAZOLE AND CINITAPRIDE IN COMBINED DOSAGE FORMS INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article A VALIDATED RP HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF OMEPRAZOLE AND CINITAPRIDE IN COMBINED

More information

Development and Validation of Stability Indicating Assay Method of Etodolac by using UV-Visible Spectrophotometer

Development and Validation of Stability Indicating Assay Method of Etodolac by using UV-Visible Spectrophotometer Research Article Development and Validation of Stability Indicating Assay Method of Etodolac by using UV-Visible Spectrophotometer Aniruddha J Palande, Shailaja B Jadhav *, Amit S Tapkir, Pravin D Chaudhari,

More information

Chapter 4: Verification of compendial methods

Chapter 4: Verification of compendial methods Chapter 4: Verification of compendial methods Introduction In order to ensure accurate and reliable test results, the quality control laboratory (QCL) needs to use analytical methods (and accompanying

More information

A Novel Stability Indicating Chromatographic Method Development And Validation For The Quantification of Tofacitinib In Pure And Its Dosage Form

A Novel Stability Indicating Chromatographic Method Development And Validation For The Quantification of Tofacitinib In Pure And Its Dosage Form IOSR Journal of Applied Chemistry (IOSR-JAC) e-issn: 2278-5736.Volume 11, Issue 2 Ver. III (February. 2018), PP 33-37 www.iosrjournals.org A Novel Stability Indicating Chromatographic Method Development

More information

Novus International Journal of Analytical Innovations 2012, Vol. 1, No. 3

Novus International Journal of Analytical Innovations 2012, Vol. 1, No. 3 Novus International Journal of Analytical Innovations 2012, Vol. 1, No. 3 ISSN 2278-6953 www.novusscientia.org Accepted on October 22, 2012 RP-HPLC method for simultaneous estimation of Avitriptan and

More information

International Journal of Pharmaceutical Research & Analysis

International Journal of Pharmaceutical Research & Analysis 149 International Journal of Pharmaceutical Research & Analysis e-issn: 2249 7781 Print ISSN: 2249 779X www.ijpra.com RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF AMBROXOL HYDROCHLORIDE

More information

Journal of Chemical and Pharmaceutical Research, 2012, 4(6): Research Article. Estimation of zaleplon by a new RP-HPLC method

Journal of Chemical and Pharmaceutical Research, 2012, 4(6): Research Article. Estimation of zaleplon by a new RP-HPLC method Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2012, 4(6):3010-3014 Research Article ISS : 0975-7384 CODE(USA) : JCPRC5 Estimation of zaleplon by a new RP-HPLC method Tentu.

More information

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs CHAPTER - 3 ANALYTICAL PROFILE 3.1 Estimation of Drug in Pharmaceutical Formulation 3.1.1 Estimation of Drugs ANALYTICAL PROFILE 84 3.1 ESTIMATION OF DRUG IN PHARMACEUTICAL FORMULATION. Agrawal A et al

More information